Nav: Home

New blood test detects early stage ovarian cancer

November 19, 2018

Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.

The new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.

A research team from the University of Adelaide and Griffith University have been studying the interactions between the toxin and an abnormal glycan (sugar) expressed on the surface of human cancer cells and released into the blood.

The team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.

A paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.

"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better. Our new test is therefore a potential game changer," says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.

Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: "Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment."

The team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.
-end-


University of Adelaide

Related Ovarian Cancer Articles:

Uncovering the mechanisms that support the spread of ovarian cancer
In this issue of the JCI, research led by Wang Min at Yale University describes how a subtype of macrophages communicate with and support tumor cell growth to drive metastasis in ovarian cancer.
Ovarian cancer study uncovers new biology
In what is believed to be the largest study of its kind, scientists at The Johns Hopkins University and the Pacific Northwest National Laboratory led a study that examined the proteomes of 169 ovarian cancer patients to identify critical proteins expressed by their tumors.
Chemotherapy may boost immunotherapy power in ovarian cancer
Cancer Research UK scientists have found that women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy.
UA engineers zero in on early detection of ovarian cancer
University of Arizona researcher Jennifer Barton is leading a two-year, $1 million project funded by the National Cancer Institute to identify imaging biomarkers of ovarian cancer, the most deadly gynecological cancer in the United States.
Ludwig Cancer Research and CRI initiate clinical trial of immunotherapy for ovarian cancer
Ludwig Cancer Research and the Cancer Research Institute (CRI) have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
Different types of ovarian cancer have different causes
The more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 National Cancer Research Institute Cancer Conference Tuesday.
Researchers isolate possible ovarian cancer biomarkers
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I-IV.
New Stand Up To Cancer-OCRF-OCNA-NOCC Ovarian Cancer Dream Team announced
The Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition $6 milion Ovarian Cancer Dream Team will focus on DNA repair pathways and therapies for ovarian cancer, seeking to expand on the recent clinical advances seen with PARP inhibitors.
Seeking new targets for ovarian cancer treatment
Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute presented today at the American Association for Cancer Research Annual Meeting 2015.
'Patchwork' ovarian cancer more deadly
The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today in PLOS Medicine.

Related Ovarian Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".